Translational Research

Rarecells is conducting a clinical study to assess the sensitivity of its new CTC-DNA technology in early stage lung cancer patients.

ISET® CTC-DNA for Early Stage Lung Cancer and Cancer Recurrence Detection.

In a collaboration with Professor Filippo Lococo from the Agostino Gemelli University and Policlinic Center of excellence in Rome, Italy, Rarecells is conducting a clinical study on early-stage operable lung cancer patients to comparatively assess the ISET® CTC-DNA and the ctDNA (standard extraction protocol) sensitivity for early cancer and cancer recurrence detection.

Scroll to Top

You're one click away from your download !

Please enter the requested information below and click SEND

You're one click away from your download !

Please enter the requested information below and click SEND

You're one click away from your download !

Please enter the requested information below and click SEND